{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:10:33Z","timestamp":1790662233936,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,3]]},"DOI":"10.7759\/cureus.39920","type":"journal-article","created":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T01:43:27Z","timestamp":1685843007000},"source":"Crossref","is-referenced-by-count":6,"title":["Immune Checkpoint Inhibitor-Induced Lymphocytic Esophagitis"],"prefix":"10.7759","author":[{"given":"Shefali","family":"Amin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salina","family":"Munankami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Altomare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian SL","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016, 16:275-87. 10.1038\/nrc.2016.36","journal-title":"Nat Rev Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler TK","year":"2016","unstructured":"Eigentler TK, Hassel JC, Berking C, et al.. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016, 45:7-18. 10.1016\/j.ctrv.2016.02.003","journal-title":"Cancer Treat Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7675","article-title":"Clinicopathologic features, treatment response, and outcomes of immune checkpoint inhibitor-related esophagitis","volume":"19","author":"Panneerselvam K","year":"2021","unstructured":"Panneerselvam K, Amin RN, Wei D, et al.. Clinicopathologic features, treatment response, and outcomes of immune checkpoint inhibitor-related esophagitis. J Natl Compr Canc Netw. 2021, 19:896-904. 10.6004\/jnccn.2020.7675","journal-title":"J Natl Compr Canc Netw"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2019.1594356","article-title":"Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors","volume":"54","author":"Tang T","year":"2019","unstructured":"Tang T, Abu-Sbeih H, Luo W, et al.. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol. 2019, 54:538-45. 10.1080\/00365521.2019.1594356","journal-title":"Scand J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0481-0","article-title":"A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy","volume":"6","author":"Horisberger A","year":"2018","unstructured":"Horisberger A, La Rosa S, Zurcher JP, Zimmermann S, Spertini F, Coukos G, Obeid M. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. J Immunother Cancer. 2018, 6:156. 10.1186\/s40425-018-0481-0","journal-title":"J Immunother Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber JS","year":"2013","unstructured":"Weber JS, Dummer R, de Pril V, Lebb\u00e9 C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013, 119:1675-82. 10.1002\/cncr.27969","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.14309\/crj.2017.57","article-title":"Severe esophagitis and gastritis from nivolumab therapy","volume":"4","author":"Boike J","year":"2017","unstructured":"Boike J, Dejulio T. Severe esophagitis and gastritis from nivolumab therapy. ACG Case Rep J. 2017, 4:e57. 10.14309\/crj.2017.57","journal-title":"ACG Case Rep J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE- 224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu AX","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, et al.. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE- 224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018, 19:940-952. 10.1016\/S1470-2045(18)30351-6","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2020-0070-RA","article-title":"Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy","volume":"145","author":"Patil PA","year":"2021","unstructured":"Patil PA, Zhang X. Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy. Arch Pathol Lab Med. 2021, 145:571-82. 10.5858\/arpa.2020-0070-RA","journal-title":"Arch Pathol Lab Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184287","article-title":"Less known gastrointestinal manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review of the literature","volume":"10","author":"Jevtic D","year":"2021","unstructured":"Jevtic D, Dumic I, Nordin T, et al.. Less known gastrointestinal manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review of the literature. J Clin Med. 2021, 10:10.3390\/jcm10184287","journal-title":"J Clin Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpccr.2020.100029","article-title":"Checkpoint inhibitor induced esophagitis with documented resolution on infliximab","volume":"2","author":"Chen FW","year":"2020","unstructured":"Chen FW, Liu AF, Srivastava A, Buchbinder E, Grover S. Checkpoint inhibitor induced esophagitis with documented resolution on infliximab. Curr Probl Cancer Case Rep. 2020, 2:100029. 10.1016\/j.cpccr.2020.100029","journal-title":"Curr Probl Cancer Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/157951-immune-checkpoint-inhibitor-induced-lymphocytic-esophagitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:04:56Z","timestamp":1707509096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/157951-immune-checkpoint-inhibitor-induced-lymphocytic-esophagitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,3]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.39920","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,3]]}}}